Current candidate TAAs for HCC TCR-T therapy include New York esophageal squamous cell carcinoma 1 (NY-ESO-1) (186), alpha-fetoprotein (AFP) (187), GPC3 (188), and human telomerase reverse transcriptase (hTERT) (189). The gene discussed is GPC3; the disease is hepatocellular carcinoma.